Sep 8, 2025, 14:24
Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
Thrombosis & Haemostasis Journal (TH Open) shared a post on X.
“Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders.
Jongejan and colleagues review the evolution of VWF-targeting therapeutic agents, their developmental stages and clinical indications.”
Read full abstract here.
Stay informed with Hemostasis Today.
-
Feb 25, 2026, 16:40Mohammed Almohammadi: Uniting Leaders in Laboratory Hematology at the 1st Saudi ISLH Joint Conference
-
Feb 25, 2026, 16:37Salihu Asimawu: Inflammation Is Not a Disease – Hats Off to the Heroes Inside Us
-
Feb 25, 2026, 16:34Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
-
Feb 25, 2026, 16:25Tagreed Alkaltham: The Blood Banker Personality
-
Feb 25, 2026, 16:17Sanjay Ahuja: Insightful Talk on 100 Years of VWD by Jorge Di Paola
-
Feb 25, 2026, 15:20Michael Shapiro։ Creating Real Pathways for Trainees in Preventive Cardiology
-
Feb 25, 2026, 15:15Ajay Kumar: Plasma Component Quality Control Standards
-
Feb 25, 2026, 15:09Wolfgang Miesbach: Efficacy, Safety and Thrombosis Signals in Haemophilia A/B with Inhibitors
-
Feb 25, 2026, 15:06Nasrin Haghani: How Vitamin K2 Reduces Arterial Plaque Buildup and Promotes Heart Health